|Day Low/High||32.18 / 33.33|
|52 Wk Low/High||17.09 / 41.57|
Jim Cramer focuses on S&P Global, Myriad Genetics, ProLogis, Emerson Electric, Ball Corp. and more.
Jim Cramer says being a realistic investor doesn't mean being negative, especially when solid reality supports optimism.
Recommends all Metastatic Prostate Cancer Patients Receive Genetic Testing
First Phase III PARP Inhibitor Clinical Trial to Use myChoice® HRD Plus as a Potential Companion Diagnostic
Investors in Myriad Genetics, Inc. saw new options become available this week, for the August 2018 expiration.
Demonstrates that EndoPredict Predicts Response to Neoadjuvant Therapy in HR+ Breast Cancer
riskScore Demonstrates Highly Statistically-Significant Ability to Predict 5-Year and Lifetime Risk of Breast Cancer in Women Who Test Negative for Hereditary Breast Cancer Mutations
2,000 Patient Study Will Leverage GeneSight Test to Guide Therapy Selection
GeneSight Demonstrated Statistically Significant Improvement in the Gold Standard Clinical Outcomes of Remission and Response
When it comes to equities investing, recurrent patterns can be of enormous importance. But for these several dozen picks, the risk/reward issues are beyond just cyclical changes.
Myriad Announces Positive Results for an EndoPredict® Clinical Study at 3rd World Congress on Controversies in Breast Cancer
Investors in Myriad Genetics, Inc. saw new options begin trading this week, for the December 15th expiration.
Positive Results Presented at the 25th World Congress of Psychiatric Genetics
Company Expects FDA Priority Review to Conclude in the Fiscal Third-Quarter 2018
The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 2,174,433 share decrease in total short interest for Myriad Genetics, Inc. , to 14,238,259, a decrease of 13.25% since 08/31/2017.
Validation of Residual Risk Score to Predict Breast Cancer Risk in Women without Hereditary Cancer Mutations Is Highly Statistically Significant
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.